Hemoglobin subunit gamma 1 and 2 promoter BCL11A-binding motifs (HBG1/HBG2 BCL11A-binding motifs)

The Hemoglobin subunit gamma 1 and 2 (HBG1 and HBG2) promoter BCL11A-binding motifs are critical DNA regulatory sequences located within the promoter regions of the genes responsible for fetal hemoglobin (HbF) production. These motifs serve as the direct binding sites for the B-cell lymphoma/leukemia 11A (BCL11A) protein, a zinc-finger transcription factor that acts as a master repressor of HbF expression in adults (Liu et al., 2018, Nature Genetics). During the developmental 'hemoglobin switch,' BCL11A binds to these specific sequences (notably around the -115 bp region relative to the transcription start site) to silence the gamma-globin genes and promote the transition to adult beta-globin production (Martyn et al., 2018, Nature Genetics). In patients with sickle cell disease or beta-thalassemia, adult hemoglobin is either mutated or absent, leading to severe anemia and organ damage. Therapeutic strategies targeting these motifs utilize advanced gene editing technologies, such as CRISPR/Cas12a (used in EDIT-301) or base editors (used in BEAM-101), to disrupt the BCL11A binding site or introduce mutations that mimic the Hereditary Persistence of Fetal Hemoglobin (HPFH) phenotype (Editas Medicine, 2024; Beam Therapeutics, 2024). By preventing the BCL11A repressor from docking at the HBG1/2 promoters, these therapies re-activate the production of fetal hemoglobin. The resulting HbF can functionally substitute for defective adult hemoglobin, preventing the polymerization of sickle hemoglobin and reducing the clinical severity of hemoglobinopathies. This approach differs from other therapies like exagamglogene autotemcel, which target the BCL11A enhancer rather than the HBG promoter motifs themselves.

Other names

HBG1/2 promoter BCL11A binding sitesFetal hemoglobin promoter repressor motifsGamma-globin promoter BCL11A binding sitesHBG1 and HBG2 distal CCAAT box region

Disruption of the BCL11A transcription factor binding site via genomic editing (CRISPR/Cas12a or base editing) to prevent transcriptional repression and induce the expression of fetal hemoglobin (HbF).